Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 959 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Arm 1- Dose Escalation Clear all

Conditions: Glioblastoma
Interventions: Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine; Drug · Radiation · Biological
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years and older
Enrollment: 2,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 42
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more

Conditions: Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC
Interventions: T3011, T3011 + pembrolizumab; Biological · Combination Product
Lead sponsor: ImmVira Pharma Co. Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 6
States / cities: Gilbert, Arizona • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more

Conditions: Solid Tumors
Interventions: Oleclumab, Durvalumab; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 11
States / cities: La Jolla, California • New Haven, Connecticut • Gainesville, Florida + 8 more

Conditions: Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Interventions: Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX), procarbazine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Brain and Central Nervous System Tumors
Interventions: terameprocol, pharmacological study; Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 9
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Ovarian Cancer, Cognitive Impairment
Interventions: N-Acetyl-Cysteine, Placebo; Drug · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Solid Tumors
Interventions: PF-03814735; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Glioblastoma Multiforme
Interventions: TPI 287, Bevacizumab; Drug
Lead sponsor: Cortice Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 9
States / cities: Birmingham, Alabama • St Louis, Missouri • Hackensack, New Jersey + 6 more

Conditions: Solid Tumors
Interventions: BI 1831169, anti-PD-1 antibody; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 16
States / cities: Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 13 more

Conditions: Healthy Volunteers
Interventions: dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device; Combination Product · Drug
Lead sponsor: Pablo Tebas; Other
Eligibility: 18 Years to 60 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stage I Breast Cancer
Interventions: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane); Other · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 50 Years to 70 Years
Enrollment: 1,670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2041
U.S. locations: 812
States / cities: Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more

Conditions: Malignant Melanoma
Interventions: Decitabine, Temozolomide, biopsy; Drug · Procedure
Lead sponsor: Hussein Tawbi; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hepatocellular Carcinoma, Liver Cancer, HCC
Interventions: MLN0128, MLN0128 (RP2D), Sorafenib; Drug
Lead sponsor: Kathy Miller; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Chicago, Illinois • Indianapolis, Indiana • Chapel Hill, North Carolina + 2 more

Conditions: Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Interventions: WTX-330; Drug
Lead sponsor: Werewolf Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 9
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions: VV-14303; Genetic
Lead sponsor: Kriya Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Chandler, Arizona • Lady Lake, Florida

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: semaglutide, oral placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 632 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 40
States / cities: Tucson, Arizona • Chula Vista, California • Long Beach, California + 34 more

Conditions: Primary Brain Tumor, Brain Tumor, Recurrent
Interventions: Fluoxetine, Temozolomide; Drug
Lead sponsor: Duke University; Other
Eligibility: 24 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: San Diego, California • Stanford, California • New York, New York + 1 more

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: filgrastim, clofarabine, melphalan, mycophenolate mofetil, tacrolimus, thiotepa, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 0 Years to 54 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumors
Interventions: RO7623066, Olaparib, Carboplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Orange, California • New Haven, Connecticut • Detroit, Maine + 12 more

Conditions: Neoplasms
Interventions: DSP-0509, DSP-0509, Pembrolizumab; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Indianapolis, Indiana • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 2 more

Conditions: Waldenstrom's Macroglobulinemia
Interventions: Mavorixafor, Ibrutinib; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Denver, Colorado • Boston, Massachusetts • Houston, Texas

Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions: Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177); Biological · Other · Drug
Lead sponsor: Beat AML, LLC; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2032
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more

Conditions: Lupus Nephritis (LN)
Interventions: Vonsetamig, Odronextamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: San Francisco, California • Gainesville, Florida • Rochester, Minnesota + 1 more

Conditions: Melanoma
Interventions: CMP-001, Pembrolizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • Duarte, California + 9 more

Search by objective public record fields.

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors

Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

dMAbs for Prevention of COVID-19

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy